Multimodal Differences in Effort-based Decision-Making in Depression
Launched by GEORGIA INSTITUTE OF TECHNOLOGY · Oct 17, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how people with major depressive disorder (MDD) make decisions that require effort, especially in everyday activities. Researchers want to better understand the challenges that come with low motivation in depression, as these challenges can affect how well someone functions in daily life. The study will involve a new test called HORMES, which will help measure motivation, brain activity, and other physical responses when participants engage in decision-making tasks that require effort.
To participate in this trial, individuals must be between 18 and 65 years old, fluent in English, and able to give consent. There are two groups: one group includes people diagnosed with major depression, while the other group will serve as a control and should not have any current psychiatric disorders. Participants can expect to take part in activities that assess their decision-making abilities and how they feel during these tasks. This study aims to bridge the gap between clinical assessments and real-life experiences, ultimately helping to improve our understanding of depression and how it affects daily decisions.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Matched control group
- • 18-65 years old
- • Able-bodied
- • Fluent in English
- • Able to give written and verbal informed consent to the proposed experiment
- • Able to comprehend the study procedure, potential risks, and benefits
- • Group with depression
- • Diagnosed with major depression
- • Quick Inventory of Depression Symptomology (QIDS) score \> 5
- • 18-65 years old
- • Able-bodied
- • Fluent in English
- • Able to give written and verbal informed consent to the proposed experiment
- • Able to comprehend the study procedure, potential risks, and benefits
- Exclusion Criteria:
- • Matched control group
- • Current diagnosed psychiatric disorder (e.g., anxiety, depression, bipolar disorder)
- • Current pregnancy
- • BMI \> 35
- • Currently on antipsychotics
- • Group with depression
- • Diagnosed with psychotic symptoms
- • Diagnosed with other neurological or psychiatric disorders
- • Current pregnancy
- • BMI \> 35
- • Currently on antipsychotics
About Georgia Institute Of Technology
The Georgia Institute of Technology, a leading public research university located in Atlanta, Georgia, is committed to advancing scientific knowledge and innovation through rigorous academic research and clinical trials. With a strong emphasis on interdisciplinary collaboration, Georgia Tech leverages its expertise in engineering, technology, and health sciences to explore novel solutions that address pressing healthcare challenges. The institution fosters an environment that promotes cutting-edge research, ethical practices, and community engagement, ensuring that its clinical trials contribute to meaningful advancements in patient care and public health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Atlanta, Georgia, United States
Patients applied
Trial Officials
Christopher J Rozell, Ph.D.
Principal Investigator
Georgia Institute of Technology
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported